Table 4.

Proportion of industry funded patient groups that disclosed information about funding. Values are numbers (percentages) unless stated otherwise

Study	Organisations that disclosed funding	Amount disclosed	Proportion of income disclosed	Use disclosed
On websites
Vitry 2011	25/78 (32)	—	—	—
Colombo 2012	46/157 (29)	3/157 (2)	0/157 (0)	25/157 (16)
Jones 2008	64/246 (26)	14/246 (6)	4/246 (2)	18/246 (7)
Rothman 2011*	40/161(25)	1/161 (1)	—	—
In consultations
Abola 2016b	20/22 (91)	—	—	—
Lin 2017	0/9 (0)†	—	—	—

^*Only refers to funding from Eli Lilly.

^†Data received from authors.